The Role of Stroma in Breast Carcinoma Growth in Vivo

[en] The malignant progression of tumors is thought to be related to the expression of oncogenes and loss of expression of tumor suppressor gene. These factors are intrinsic to the cancer cells themselves. However, carcinomas are also infiltrated by host cells (fibroblasts, endothelial cells, inflammatory cells) and surrounded by an extracellular matrix which is extensively remodeled. The extracellular matrix components and infiltrating host cells provide a microenvironment that conditions both tumor progression and the metastatic process. Transplantation of human tumors into athymic nude mice has become an important experimental approach to study the biology of human cancers. The different models developed so far are beginning to elucidate the role of matrix molecules, growth factors and enzymes as well as fibroblasts in tumor progression. These animal models are likely to provide a useful tool to evaluate new antitumor treatments.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme

Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique

Language :

English

Title :

The Role of Stroma in Breast Carcinoma Growth in Vivo

Publication date :

April 1998

Journal title :

Journal of Mammary Gland Biology and Neoplasia

ISSN :

1083-3021

eISSN :

1573-7039

Publisher :

Kluwer Academic/Plenum Publishers, New York, United States - New York

Volume :

Issue :

Pages :

215-25

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 July 2009

Statistics

Number of views

100 (2 by ULiège)

Number of downloads

173 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

S. E. LaFlamme and K. L. Auer (1996). Integrin signaling. Sem. Cancer Biol. 7:111-118.
V. M. Weaver, A. H. Fisher, O. W. Peterson, and M. J. Bissel (1997). The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem. Cell Biol. 74:833-851.
S. M. Frisch, and H. Francis (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:619-626.
C. H. Streuli, C. Schmidhauser, N. Bailey, P. Yurchenco, A. P. N. Skubitz, C. Roskelley, and M. J. Bissell (1995). Laminin mediates tissue-specific gene expression in mammary epithelia. J. Cell Biol 129:591-603.
C. Streuli and G. Edwards (1998). Control of normal mammary epithelial phenotype by integrins. J. Mam. Gland Biol. Neoplasia 3:xx-xx.
A. Lochter, A. Srebrow, C. J. Sympson, N. Terracio, Z. Werb, and M. J. Bissell (1997). Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J. Biol. Chem. 272:5007-5015.
L. A. Rudolph-Owen and L. M. Matrisian (1998). Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. J. Mam. Gland Biol. Neoplasia 3:177-190.
M. Mareel, M. E. Bracke, F. Van Roy, and P. de Baetselier (1997). Molecular mechanisms of cancer invasion. In Encyclopedia of Cancer, (Vol. II), Academic Press, Inc., pp. 1072-1083.
H. F. Dvorak (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-1659.
J. Folkman (1995). Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1:27-31.
M. C. Rio, O. Lefebvre, M. Santavicca, A. Noël, M. P. Chenard, P. Anglard, J. A. Byrne, A. Okada, C. H. Régnier, R. Masson, J. P. Bellocq, and P. Basset (1996). Stromelysin-3 in the biology of the normal and neoplastic mammary gland. J. Mam. Gland Biol. Neoplasia 1:231-240.
M. Grégoire and B. Lieubeau (1995). The role of fibroblasts in tumor behavior. Cancer Metastasis Rev. 14:339-350.
N. Wernert (1997). The multiple roles of tumor stroma. Virchows Arch. 430:433-443.
D. Verhoeven, N. Bourgeois, A. Noël, J. M. Foidart, and N. Buyssens (1990). The presence of a type IV collagen skeleton associated with periductal elastosis in breast cancer. J. Histochem. Cytochem. 38:245-255.
H. Kosmehl, A. Berndt, and D. Katenkamp (1996). Molecular variants of fibronectin and laminin: Structure, physiological occurrence and histopathological aspects. Virchows Arch. 429:311-322.
K. Henning, H. Kosmehl, A. Berndt, P. Rousselle, and D. Gabler Katenkamp (1995). Differential expression of laminin chains is benign and malignant lesions of the breast. Pathol. Res. Pract. 191:175.
A. Bellahcène, S. Menard, R. Bufalino, L. Moreau, and V. Castronovo (1996). Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int. J. Cancer 69: 350-353.
S. Peyrol, M. Raccurt, F. Gerard, C. Gleyzal, J. A. Grimaud, and P. Sommer (1997). Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am. J. Pathol. 150:497-507.
A. Noël, C. Munaut, A. Boulvain, C. M. Calberg-Bacq, Ch. A. Lambert, B. Nusgens, Ch. M. Lapière, and J. M. Foidart (1992). Modulation of collagen and fibronectin synthesis in fibroblasts by normal and malignant cells. J. Cell. Biochem. 48:150-161.
M. J. Merrilees and G. J. Finlay (1985). Human tumor cells in culture stimulate glycosaminoglycan synthesis by human skin fibroblasts. Lab. Invest. 53:30-36.
L. Ronnov-Jenssen, O. W. Petersen, V. E. Koteliansky, and M. J. Bissell (1995). The origin of the myofibroblasts in breast cancer: Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Invest. 95:859-873.
A. B. Unden, B. Sandstedt, K. Bruce, M. A. Hedblad, and M. Ståhle-Bäckdahl (1996). Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermafibrosarcoma but not in dermatofibrosarcoma. J. Invest. Dermatol. 107:147-153.
R. Clarke (1996a). Human breast cancer cell line xenografts as models of breast cancer - the immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Br. Cancer Res. Treat. 39:69-86.
R. Clarke (1996b). Animal models of breast cancer: Their diversity and role in biomedical research. Br. Cancer Res. Treat. 39:1-6.
A. L. Harris, H. Zhang, A. Moghaddam, S. Fox, P. Scott, A. Pattison, K. Gatter, I. Stratford, and R. Bicknell (1996). Breast cancer angiogenesis - new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Br. Cancer Res. Treat. 38:97-108.
S. W. McLeskey, L. Zhang, S. Kharbanda, J. Kurebayashi, M. E. Lippman, R. B. Dickson, and F. G. Kern (1996). Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Br. Cancer Res. Treat. 39:103-117.
S. R. Wolman, G. H. Heppner, and E. Wolman (1997). New directions in breast cancer research. FASEB J. 11:535-543.
J. E. Price (1996). Metastasis from human breast cancer cell lines. Br. Cancer Res. Treat. 39:93-102.
R. R. Mehta, J. M. Graves, G. D. Hart, A. Shilkaitis, and T. K. Das Gupta (1993). Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Br. Cancer Res. Treat. 25:65-71.
N. Brünner, E. W. Thompson, M. Spang-Thomsen, J. Rygaard, K. Danø, and J. A. Zwiebel (1992). LacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur. J. Cancer 28A: 1989-1995.
C. Manzotti, R. A. Audisio, and G. Pratesi (1993). Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin. Exp. Metastasis 11:5-14.
M. Taub, Y. Wang, T. M. Szcesny, and H. K. Kleinman (1990). Epidermal growth factor or transforming growth factor a is required for kidney tubologenesis in Matrigel cultures in serum-free medium. Proc. Natl. Acad. Sci. U.S.A. 87:4002-4006.
S. Baatout (1997). Endothelial differentiation using Matrigel (Review). Anticancer Res. 17:451-456.
A. Noël, V. Borcy, M. Bracke, C. Gilles, J. Bernard, P. Birembaut, M. Mareel, and J. M. Foidart (1995). Heterotransplantation of primary and established human tumour cells in nude mice. Anticancer Res. 15:1-8.
A. Noël, N. Simon, J. Raus, and J. M.Foidart (1992). Basement membrane components (Matrigel) promote human breast adenocarcinoma MCF7 cells tumorigenicity and provide an in vivo model to assess cell responsiveness to estrogen. Biochem. Pharmacol. 43:1263-1267.
R. Fridman, G. Giaccone, T. Kanemoto, G. R. Martin, A. F. Gazdar, and J. L. Mulshine (1990). Reconstituted basement membrane (Matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. 87:6698-6702.
R. Fridman, M. C. Kibbey, L. S. Royce, M. Zain, T. M. Sweeney, D. L. Jicha, J. R. Yannelli, G. R. Martin, and H. K. Kleinman (1991). Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J. Natl. Cancer Inst. 83:769-775.
P. Topley, D. C. Jenkins, E. A. Jessup, and J. N. Stables (1993). Effect of reconstituted basement membrane components on the growth of a panel human tumour cell lines in nude mice. Brit. J. Cancer 67:953-958.
T. Lopez-Conejo, N. Olmo, J. Turnay, J. Navarro, and A. Lizarbe (1996). Characterization of tumorigenic sub-lines from a poorly tumorigenic human colon-adenocarcinoma cell line. Int. J. Cancer 67:668-675.
P. Mullen, A. Ritchie, S. P. Langdon, and W. R. Miller (1996). Effect of matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int. J. Cancer 67:816-820.
A. Passaniti, J. T. isaacs, J. A. Haney, S. W. Adler, T. J. Cujdik, P. V. Long, and H. K. Kleinman (1992). Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int. J. Cancer 51:318-324.
D. S. Grant, M. C. Kibbey, J. L. Kinsella, M. C. Cid, and H. K. Kleinman (1994). The role of basement membrane in angiogenesis and tumor growth. Path. Res. Pract. 190: 854-863.
Y. Ito, Y. Iwamoto, K. Tanaka, K. Okuyama, and Y. Sugioka (1996). A quantitative assay using basement membrane extracts to study tumor angiogenesis in vivo. Int. J. Cancer 67:148-152.
R. D. Bonfil, A. Vinyals, O. D. Bustuoabad, A. Llorens, F. J. Banavides, M. Gonzales-Garrigues, and A. Fabra (1994). Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int. J. Cancer 58:233-239.
T. Kanemoto, R. Reich, L. Royce, D. Greatorex, S. H. Adler, N. Shiraishi, G. R. Martin, Y. Yamada, and H. K. Kleinman (1990). Identification of an amino acid sequence from the laminin-A chain that stimulates metastasis and collagenase-IV production. Proc. Natl. Acad. Sci. U.S.A. 87:2279-2283.
S. Stack, R. D. Gray, and S. V. Pizzo. (1991). Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain. Biochemistry 30:2073-2077.
R. S. Bresalier, B. Schwartz, Y. S. Kim, Q. Y. Duh, H. K. Kleinman, and P. M. Sullam (1995). The laminin al chain Ile-Lys-Val-Ala-Val (IKVAV)-containing peptide promotes liver colonization by human colon cancer cells. Cancer Res. 55:2476-2480.
Y. Iwamoto, M. Nomizu, Y. Yamada, Y. Ito, K. Tanaka, and Y. Sugioka (1996). Inhibition of angiogenesis, tumour growth and experimental metastasis of human fibrosarcoma cells HT1080 by a multimetric form of the laminin sequence Tyr-Ile-Gly-Ser-Arg (YIGSR). Brit. J. Cancer 73:589-595.
A. Noël, H. Emonard, M. Polette, P. Birembaut, and J. M. Foidart (1994). Role of matrix, fibroblasts and type IV collagenases in tumor progression and invasion. Pathol. Res. Pract. 190:934-941.
A. Noël, M. C. De Pauw-Gillet, G. Purnell, B. Nusgens, Ch. M. Lapière, and J. M.Foidart (1993). Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by Matrigel and fibroblasts. Brit. J. Cancer 68:909-915.
C. E. P. van Roozendaal, B. van Ooijen, J. G. M. Klijn, C. Claassen, A. M. M. Eggermont, S. C. Henzen-Logmans, and J. A. Foekens (1992). Stromal influences on breast cancer cell growth. Brit. J. Cancer 65:77-81.
J. L. Camps, S. M. Chang, T. C. Hsu, M. R. Freeman, S. J. Hong, H. E. Zhau, A. C. von Eschenbach, and L. W. K. Chung (1990). Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. U.S.A. 87:75-79.
H. Birkedal-Hansen (1995). Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:728-735.
K. J. Heppner, L. M. Matrisian, R. A. Jensen, and W. H. Rodgers (1996). Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149:273-282.
A. Noël, O. Lefebvre, E. Maquoi, L. Vanhoorde, M. P. Chenard, M. Māreel, J. M. Foidart, P. Basset, and M. C. Rio (1996). Stromelysin-3 expression promote tumor take in nude mice J. Clin. Invest. 97:1924-1930.
H. Pulyaeva, J. Bueno, M. Polette, P. Birembaut, H. Sato, M. Seiki, E. W. Thompson (1997). MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin. Exp. Metastasis 15:111-120.
J. R. MacDougall and L. M. Matrisian (1995). Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:351-362.
D. C. Talbot and P. D. Brown (1996). Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer 14:2528-2533.
Y. A. DeClerck, N. Perez, H. Shimada, T. C. Boone, K. E. Langley, and S. M. Taylor (1992). Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:701-708.
S. Imren, D. B. Kohn, H. Shimada, L. Blavier, and Y. A. DeClerck (1996). Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 56:2891-2895.
J. A. Low, M. D. Johnson, E. A. Bone, and R. B. Dickson (1996). The matrix metalloproteinase inhibitor Batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. 2:1207-1214.
M. Wang, Y. E. Liu, J. Greene, S. Sheng, A. Fuchs, E. M. Rosen, Y. E. Shi (1997). Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14:2767-2774.
M. P. Chenard, L. O'Siorain, S. Shering, N. Rouyer, Y Lutz, C. Wolf, P. Basset, J. P. Bellocq, and M. J. Duffy (1996). High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer (Pred. Oncol.) 69:448-451.
J. Taipale and J. Keski-Oja (1997). Growth factors in the extra-cellular matrix. FASEB J. 11:51-59.
J. L. Fowlkes, J. J. Enghild, K. Suzuki, and H. Nagase (1994). Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269:25742-25746.
E. Levi, R. Fridman, H. Q. Miao, Y. S. Ma, A. Yayon, and I. Vlodavsky (1994) Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Nad. Acad. Sci. U.S.A. 93:7069-7074.